Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBT (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed EBT for 15 consecutive years, with $31.5 million as the latest value for Q4 2025.

  • Quarterly EBT rose 328.74% to $31.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.8 million through Dec 2025, up 531.26% year-over-year, with the annual reading at $95.8 million for FY2025, 531.26% up from the prior year.
  • EBT hit $31.5 million in Q4 2025 for Ani Pharmaceuticals, down from $33.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $33.8 million in Q3 2025 to a low of -$31.5 million in Q3 2024.
  • Historically, EBT has averaged -$1.3 million across 5 years, with a median of -$1.1 million in 2021.
  • Biggest five-year swings in EBT: tumbled 25997.0% in 2022 and later soared 1051.59% in 2024.
  • Year by year, EBT stood at -$30.9 million in 2021, then skyrocketed by 81.31% to -$5.8 million in 2022, then surged by 116.43% to $947000.0 in 2023, then crashed by 1553.22% to -$13.8 million in 2024, then skyrocketed by 328.74% to $31.5 million in 2025.
  • Business Quant data shows EBT for ANIP at $31.5 million in Q4 2025, $33.8 million in Q3 2025, and $10.5 million in Q2 2025.